Cargando…
DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
BACKGROUND AND OBJECTIVES: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients with untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of e...
Autores principales: | Muntoni, Francesco, Signorovitch, James, Sajeev, Gautam, Lane, Henry, Jenkins, Madeline, Dieye, Ibrahima, Ward, Susan J., McDonald, Craig, Goemans, Nathalie, Niks, Erik H., Wong, Brenda, Servais, Laurent, Straub, Volker, Guglieri, Michela, de Groot, Imelda J.M., Chesshyre, Mary, Tian, Cuixia, Manzur, Adnan Y., Mercuri, Eugenio, Aartsma-Rus, Annemieke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103111/ https://www.ncbi.nlm.nih.gov/pubmed/36725339 http://dx.doi.org/10.1212/WNL.0000000000201626 |
Ejemplares similares
-
Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2019) -
Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
por: Ayyar Gupta, Vandana, et al.
Publicado: (2023) -
Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015) -
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration
por: Goemans, Nathalie, et al.
Publicado: (2020) -
Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2023)